Isoniazid-resistant TB and associated factors in Ethiopia
Authors:
Open Access
- 1 June 2025
- journal article
- Published by International Union Against Tuberculosis and Lung Disease in Public Health Action
- Vol. 15 (2) , 76-81
Abstract
BACKGROUND: Isoniazid-resistant, rifampicin-susceptible Mycobacterium tuberculosis (Hr-TB) is the most common form of drug-resistant TB (DR-TB). We investigated the prevalence of and risk factors for Hr-TB in Ethiopia. METHODS: A cross-sectional study was conducted to determine the magnitude of Hr-TB, and to compare characteristics of persons with Hr-TB to those with multidrug-resistant TB (MDR-TB) and INH/RMP-susceptible TB identified during the National Drug Resistance Survey from 2017–2019. RESULTS: Among 1927 M. tuberculosis isolates recovered from persons with pulmonary TB, the prevalence of Hr-TB was 4.1% (95% CI 3.2-5.1), whereas the prevalence of MDR-TB was 1.9%. (95% CI 1.3–2.6). Unlike MDR-TB, the occurrence of Hr-TB did not differ significantly between new and previously treated TB cases ( P = 0.67). The prevalence of Hr-TB cases was high in the Amhara (8.0%, 95% CI 4.8–12.5) region and Addis Ababa (7.1%, 95% CI 3.4–13.0). The proportion of Hr-TB increased with age (OR 1.02, 95% CI 1.01–1.04; P = 0.035). Compared to INH/RMP-susceptible TB, Hr-TB was more likely to harbor resistance to ethambutol, streptomycin and pyrazinamide ( P < 0.0001). CONCLUSIONS: Hr-TB is the most prevalent type of DR-TB in Ethiopia and varies among regional states. Given the lack of identifiable clinical factors associated with Hr-TB, we recommend screening all bacteriologically confirmed TB cases for INH resistance at baseline.Keywords
This publication has 22 references indexed in Scilit:
- Drug-resistant tuberculosis: a persistent global health concernNature Reviews Microbiology, 2024
- Isoniazid-monoresistant tuberculosis in France: Risk factors, treatment outcomes and adverse eventsInternational Journal of Infectious Diseases, 2021
- First molecular-based anti-TB drug resistance survey in EritreaThe International Journal of Tuberculosis and Lung Disease, 2021
- Isoniazid Monoresistance and Rate of Culture Conversion among Patients in the State of Georgia with Confirmed Tuberculosis, 2009–2014Annals of the American Thoracic Society, 2018
- Treatment of isoniazid-resistant tuberculosis with first-line drugs: a systematic review and meta-analysisThe Lancet Infectious Diseases, 2017
- Genomic analysis of globally diverse Mycobacterium tuberculosis strains provides insights into the emergence and spread of multidrug resistanceNature Genetics, 2017
- Determination of risk factors for isoniazid monoresistance and multidrug-resistant tuberculosis in treatment failure patientsScandinavian Journal of Infectious Diseases, 2011
- The impact and cost-effectiveness of strategies to detect drug-resistant tuberculosisEuropean Respiratory Journal, 2011
- Epidemiology of antituberculosis drug resistance 2002–07: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance SurveillanceThe Lancet, 2009
- Clinical Characteristics and Treatment Outcomes of Patients with Isoniazid‐Monoresistant TuberculosisClinical Infectious Diseases, 2009